Edgar Lee Net Worth

The estimated Net Worth of Edgar Lee is at least $1.28 Миллиард dollars as of 15 December 2017. Mr. Lee owns over 6,000 units of Sorrento Therapeutics Inc stock worth over $60 and over the last 14 years he sold SRNE stock worth over $1,277,527,040. In addition, he makes $215,250 as Independent Director at Sorrento Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Lee SRNE stock SEC Form 4 insiders trading

Edgar has made over 11 trades of the Sorrento Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of SRNE stock worth $51,480 on 15 December 2017.

The largest trade he's ever made was selling 7,064,036 units of Sorrento Therapeutics Inc stock on 1 May 2013 worth over $674,615,438. On average, Edgar trades about 922,739 units every 127 days since 2011. As of 15 December 2017 he still owns at least 6,000 units of Sorrento Therapeutics Inc stock.

You can see the complete history of Mr. Lee stock trades at the bottom of the page.

Edgar Lee biography

Edgar Lee serves as Independent Director of the Company. Mr. Lee is currently a Managing Director at Oaktree Capital Management. Mr. Lee founded and was the portfolio manager of Oaktree's $5.5bn Strategic Credit strategy. He was also the Chief Executive Officer and Chief Investment Officer of Oaktree's three business development companies (BDCs) including Oaktree Specialty Lending (Nasdaq: OCSL) and Oaktree Strategic Income Corporations (Nasdaq: OCSI). Prior to joining Oaktree in 2007, Mr. Lee worked at UBS Investment Bank in Los Angeles and Lehman Brothers in New York. He received a B.A. degree in economics from Swarthmore College and his master's degree from Harvard University. Mr. Lee serves as a director of Neo Performance Materials (TSX: NEO) and previously served on the boards of Nine Entertainment and Charter Communications.

What is the salary of Edgar Lee?

As the Independent Director of Sorrento Therapeutics Inc, the total compensation of Edgar Lee at Sorrento Therapeutics Inc is $215,250. There are 9 executives at Sorrento Therapeutics Inc getting paid more, with Jaisim Shah having the highest compensation of $10,971,100.

How old is Edgar Lee?

Edgar Lee is 43, he's been the Independent Director of Sorrento Therapeutics Inc since 2019. There are 10 older and 2 younger executives at Sorrento Therapeutics Inc. The oldest executive at Sorrento Therapeutics Inc is Dr. Michael A. Royal, 67, who is the SVP & Chief Medical Officer.

What's Edgar Lee's mailing address?

Edgar's mailing address filed with the SEC is C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTORS PLACE, SAN DIEGO, CA, 92121.

Insiders trading at Sorrento Therapeutics Inc

Over the last 15 years, insiders at Sorrento Therapeutics Inc have traded over $17,198,839 worth of Sorrento Therapeutics Inc stock and bought 10,353,437 units worth $10,703,222 . The most active insiders traders include Jane Ph D Hsiao, Edgar Lee и Patrick Chan Soon Shiong Fa.... On average, Sorrento Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $2,947. The most recent stock trade was executed by Henry Ji on 7 September 2022, trading 88,888 units of SRNE stock currently worth $179,554.

What does Sorrento Therapeutics Inc do?

sorrento therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical car-t therapies targeting solid tumors.

Complete history of Mr. Lee stock trades at Charter Communications, Sorrento Therapeutics Inc, Oaktree Specialty Lending Corp и Oaktree Strategic Income Corp

Sorrento Therapeutics Inc executives and stock owners

Sorrento Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jaisim Shah,
  Director
• Henry Ji,
  Chairman of the Board, President, Chief Executive Officer, Co-Founder
• Dr. Henry H. Ji Ph.D.,
  Chairman, Pres & CEO
• Najjam Asghar,
  Sr. VP & CFO
• Kim Janda,
  Director
• Yue Wu,
  Independent Director
• Dorman Followwill,
  Lead Independent Director
• David Lemus,
  Independent Director
• Robin Smith,
  Independent Director
• Edgar Lee,
  Independent Director
• Najjam Asghar,
  Chief Financial Officer
• William J. Farley,
  VP of Sales & Bus. Devel.
• Dr. Robert D. Allen Ph.D.,
  Sr. VP of Antiviral & Immunotherapy
• Brian Cooley,
  Sr. VP of Lymphatic Drug Delivery BU Leader
• Dr. Shawn Sahebi Ph.D.,
  Sr. VP of Strategy & Analytics
• Dr. Mark R. Brunswick,
  Sr. VP of Regulatory Affairs
• Dr. Alexis Nahama,
  Sr. VP & Head of RTX Program
• Dr. Michael A. Royal,
  SVP & Chief Medical Officer
• Bill Farley,
  VP of Sales & Bus. Devel.
• Brian Sun,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Jane Ph D Hsiao,
  Director
• Management Ltd Abg Srne Ltd...,
  
• Douglas O Ebersole,
  Director
• Jeffrey Su,
  Executive VP and COO
• Kevin Herde,
  Executive VP and CFO
• William S Marth,
  Director
• Management Ltd Abg Srne Ltd...,
  
• George K Ng,
  See Remarks
• Patrick Chan Soon Shiong Fa...,
  
• Jerome B Zeldis,
  See Remarks
• David H Deming,
  Director
• Antonius Schuh,
  Chairman and CEO
• Steve Zaniboni,
  Director
• Curtis Lockshin,
  Director
• Donald R Scifres,
  10% owner
• Diane D S Tang Liu,
  Director
• Glenn L Halpryn,
  Director
• Charles P Rodi,
  VP, Research & Development
• Martina Molsbergen,
  VP, Business Development
• Dean Ferrigno,
  Chief Accounting Officer
• Pacific Med Tech (Bvi) Ltd ...,
  
• Management Ltd Abg Srne Ltd...,
  
• Management Ltd Abg Ii So Lt...,
  
• Jiong Shao,
  Chief Financial Officer
• Zhenwei Miao,
  Chief Technology Officer
• George Uy,
  Chief Commercial Officer
• Patrickmp 13 Ventures, Llc ...,
  
• Michael Scott Salka,
  Director
• Health, Inc. Opko,
  10% owner
• Mark Durand,
  Director
• Richard G Vincent,
  Chief Financial Officer
• Cam Gallagher,
  Director
• David Ritchie Webb,
  Director
• Ernst Guenter Afting,
  Director
• Vuong Trieu,
  CSO
• Elizabeth Czerepak,
  EVP & Chief Financial Officer
• Tammy Reilly,
  Director